However, nowadays there is a lot of evidence showing that CD133 is considered a biomarker for several types of cancer, including ovarian cancer, colorectal cancer, lung cancer, breast cancer, hepatocellular cancer or gastric cancer [99,100,101,102,103,104,105,106,107,108,109] (Table 1). This evidence concerns the gene PROM1 and ovarian carcinoma.